Paraoxonase gene polymorphism and coronary artery disease in Indian subjects

International Journal of Cardiology

Volumn 66, Issue 2, 1998, Pages 165-168

  Pati, Nirupma ^a   Pati, Uttam ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Coronary artery disease; Indian subjects; Paraoxonase; Polymorphism

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; GLUTAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; ESTERASES; HUMANS; INDIA; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0032582201     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00209-5     Document Type: Article

References (13)

1. [1] Mackness MI, Arrol S, Abbott CA, Durrington PN. Is paraoxonase related to atherosclerosis. Chem Biol Interactions 1993;87:161-71.
2. [2] La Du, B.N. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 51-91.
3. [3] Adkins SS, Can KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191 for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
4. [4] Suehiro T, Nakauchi Y, Yammamoto M, Arii K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiology 1996;57:69-73.
5. [5] Serrato M, Marian AJ. A variant of human paraoxonase arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995;96:3005-8.
6. [6] Ruiz J, Blanche H, James RW, Blatter-Garin MC, Vaisse C, Charpentier G. Gln-Arg 192 polymorphism of paraoxonase and coronary artery disease in type 2 diabetes. Lancet 1995;346:869-72.
7. [7] Blatter-Garin MC, James RW, Messmer S, Barja F, Pometta D. Quantification of human serum paraoxonase by enzyme linked immunoassay: population differences in protein concentrations. Biochem J 1994;304:549-54.
8. [8] Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-38.
9. [9] Steinberg D, Parthasarthy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low density lipoprotein that increase its atherogenecity. New Eng J Med 1989;320:915-24.
10. [10] Esterbauer H, Dieber-Rothender M, Waeg G, Striegl G, Jurgens G. Biochemical structural and functional properties of low density lipoproteins. Chem Res Toxicol 1990;3(2):77-92.
11. [11] Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low density lipoproteins in NIDDM. Diabetes 1995;44:60-6.
12. [12] Lyons T. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med 1991;8:411-9.
13. [13] Haffner SM, Agil A, Mykaanan L, Stern MP, Jialal I. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance and NIDDM. Diabetes care 1995;18:646-53.